Manulife Financial (MFC) Earnings Date & Reports

Manulife delivered core earnings of C$1,836 million for Q1 2026, an 8% increase on CER from C$1,767 million in Q1 2025. Net income attributed to shareholders reached C$1,147 million, up from C$485 million last year. Core EPS of C$1.06 grew 11% CER, missing consensus estimates of C$1.09, while diluted EPS jumped to C$0.65. Core ROE rose to 16.5% from 15.6%, and the LICAT ratio held at 136%, signaling robust capital position.

Insurance sales metrics exceeded prior year: APE sales hit C$2,821 million (+7%), new business CSM C$1,019 million (+16% CER), and NBV C$944 million (+7%). Asia led with core earnings (US$) up 22% to US$598 million and NBV +15%. Canada dipped 6% to C$352 million, U.S. (US$) fell 4% to US$241 million due to lower spreads, and Global WAM edged up 2% to C$448 million despite US$4.4 billion net outflows. The company returned C$1.2 billion to shareholders. No specific revenue figure was highlighted, consistent with focus on core metrics over GAAP revenue.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.

Market Reaction and Investor Sentiment

Following the May 13 after-market release, MFC shares declined approximately 2.5% in extended trading to around $39.27 from a $39.84 close, reflecting disappointment over the core EPS miss versus C$1.09 consensus and core ROE not accelerating further. Global WAM's shift to net outflows from prior inflows also weighed, offsetting insurance beats. Sentiment remains balanced, with praise for Asia strength and capital returns but caution on U.S./Canada softness and outflows. Analysts continue to focus on execution toward ROE goals.

Forward Outlook and Key Factors to Monitor

Manulife affirmed its positioning to meet long-term targets, including mid-teens core ROE and LICAT above 130%, supported by Q1's 136% ratio and excess capital enabling $1.2 billion returns. Investors should watch progress on strategic priorities like expanding health offerings in Asia and Canada, Global WAM partnerships (e.g., L&G, recent Schroders Indonesia acquisition adding $3.5 billion AUM), and U.S. product differentiation.

Upcoming catalysts include Q2 earnings in August, where sustained APE growth and NBV margin expansion (Asia at 38.2%) could signal demand resilience. Monitor Global WAM net flows amid eMPF transitions and equity markets; Q1 outflows highlight volatility risks. Expense efficiency (46% ratio) and AI deployments boosting productivity by 30% offer margin upside.

Industry dynamics like interest rate paths will impact investment spreads, especially in U.S./Canada. Credit trends, ECL (expected credit losses), and FX headwinds (strong CAD) remain risks. Balanced capital deployment—dividends, buybacks, bolt-on M&A (mergers and acquisitions)—will be key amid regulatory focus.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations